Rituximab as monotherapy and in combination with methotrexate or leflunomide in rheumatoid arthritis: a prospective cohort study in a Peruvian hospital.

Reumatologia · 2026 · PMC13022964 · PMID 41909067

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Similarly, in the binary logistic regression model (dependent variable: achievement of ACR70 at week 48), the use of RTX monotherapy showed a favorable trend (adjusted OR = 1.48; 95% CI: 0.89–2.46), although not statistically significant ( p = 0.11).

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.